Abstract:Introduction The heart requires a high-energy production, but its metabolic capacity declines in the failing heart. Cardiac expression of nicotinamide phosphoribosyl transferase (NAMPT), the major enzyme in the salvage pathway of nicotinamide adenine dinucleotide (NAD+) synthesis, is depressed in several models of heart failure (HF), resulting in deficient NAD+ biosynthesis. However, it is unclear if NAMPT deficiency and reduced NAD pools directly cause systolic HF. Recent studies also show increased expression of nicotinamide riboside kinase 2 (NMRK2), which uses nicotinamide riboside (NR) as substrate in NAD+ biosynthesis. Objective To reproduce the NMRK2/NAMPT ratio imbalance observed in failing hearts using CRISPR/Cas9 in human induced pluripotent stem cells-derived cardiomyocytes (iPSC-CMs) and investigate the efficacy of NR supplementation to compensate for NAD+ depletion. Method Two healthy control iPSC lines were used for CRISPR/Cas9 editing to disrupt NAMPT expression. The obtained clones were then differentiated into cardiomyocytes. NAMPT knockdown (KD) and NAD biosynthesis were confirmed by western blotting and colorimetric assay, respectively. A model of ring-shaped cardiac organoids was used to compare the contractile properties of cardiomyocytes. NR treatment was performed for 72 h at 500 μM. Results We generated two heterozygous NAMPT-KD iPSC clones, carrying a deletion around the ATG codon in NAMPT exon 1. This deletion results in a 60% loss of NAMPT expression, which is maintained during differentiation into iPSC-CMs. In NAMPT-KD cardiomyocytes, the NAD+ levels were significantly reduced compared to WT cardiomyocytes (190.1 ± 71.86 vs. 306.9 ± 125.6 pmol/million cells, P < 0.01). At the functional level, we found no difference in mitochondrial oxidative metabolism as measured by the Seahorse analyzer. Nonetheless, NAMPT-KD cardiac organoids exhibit contractile dysfunction with significantly lower amplitude, maximum contraction and relaxation velocities as compared to wild-type organoids. We found that NR treatment in NAMPT-KD CMs resulted in a net increase in NAD+ levels (228 vs. 490 pmol/million cells). Furthermore, NR supplementation was sufficient to attenuate the development of contractile dysfunction in NAMPT-KD organoids. Conclusion NAMPT-deficient human iPSC-CMs reproduce the metabolic pattern observed in the failing hearts and show contractility dysfunction. This supports the restoration of NAD pools as a novel targeted pharmacological approach for HF.

Cardiac NAD+ depletion in mice promotes hypertrophic cardiomyopathy and arrhythmias prior to impaired bioenergetics

NAD+ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy

Short-term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure.

Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload

Cardiomyocytes-derived from NAMPT deficient human induced pluripotent stem cells exhibit reduced NAD pools and contractility dysfunction

Control of NAD+ homeostasis by autophagic flux modulates mitochondrial and cardiac function

The Role of NAD+ in Myocardial Ischemia-induced Heart Failure in Sprague-Dawley Rats and Beagles

Protection Effect of Nicotinamide on Cardiomyoblast Hypoxia/re-Oxygenation Injury: Study of Cellular Mitochondrial Metabolism.

ACMSD Mediated De Novo NAD+ Biosynthetic Impairment in Cardiac Endothelial Cells As a Potential Therapeutic Target for Diabetic Cardiomyopathy.

Abstract P3187: Deletion Of SARM1 NAD Hydrolase Ameliorates Diabetic Cardiomyopathy By Regulating Mitochondrial Metabolism And Mitophagy

The Efficacy of Risk Factor Modification Compared to NAD+ Repletion in Diastolic Heart Failure

Nicotinamide Restores Tissue NAD+ and Improves Survival in Rodent Models of Cardiac Arrest.

Mitochondrial Complex I Deficiency Increases Protein Acetylation and Accelerates Heart Failure.

NAD<SUP>+</SUP> and cardiovascular diseases

[Expression and Initial Mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in Dilated Cardiomyopathy].

The role of nicotinamide adenine dinucleotide salvage enzymes in cardioprotection

NAD+: A Key Metabolic Regulator with Great Therapeutic Potential for Myocardial Infarction Via Sirtuins Family

NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia

Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases

Emerging interactions between mitochondria and NAD+ metabolism in cardiometabolic diseases

Abstract 12474: Nicotinamide Restores Tissue Nad + and Improves Outcomes in a Murine Model of Cardiac Arrest